CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM097905
035-os BibID:(WoS)000784212600006 (Scopus)85118725064
Első szerző:Juhász Márk Félix
Cím:The EFFect of dietary fat content on the recurrence of pancreaTitis (EFFORT) : protocol of a multicenter randomized controlled trial / Juhász Márk Félix, Vereczkei Zsófia, Ocskay Klementina, Szakó Lajos, Farkas Nelli, Szakács Zsolt, Zádori Noémi, Wilschanski Michael, Pandol Stephen J., Joly Francisca, Capurso Gabriele, Arcidiacono Paolo Giorgio, Izbéki Ferenc, Czakó László, Papp Mária, Czopf László, Hegyi Péter Jr., Párniczky Andrea, Hungarian Pancreatic Study Group
Dátum:2022
ISSN:1424-3903
Megjegyzések:Background: Around 20% of patients with acute pancreatitis (AP) will develop acute recurrent pancreatitis (ARP) and 10% will progress to chronic pancreatitis. While interventions to avoid recurrences exist for the two most common causes - abstinence for alcoholic and cholecystectomy for biliary pancreatitis - the are no known preventive measures in idiopathic ARP. Though it is not included in any of the guidelines, a low-fat diet is often recommended. Our aim is to test dietary fat reduction's effect on AP recurrence in a randomized controlled setting, in order to provide high-quality evidence for the validity of such an intervention. Methods, design: Participants with at least 2 episodes of AP in the preceding 2 years of which the last episode was idiopathic will be randomized to one of two diets with different fat contents: a 'reduced fat diet' (15% fat, 65% carbohydrate, 20% protein) and a 'standard healthy diet' (30% fat, 50% carbohydrate, 20% protein; based on WHO recommendations). Participants will be followed-up for 2 years (visits will be scheduled for months 3, 6, 12, 18 and 24) during which they will receive a repeated session of nutritional guidance, complete food frequency questionnaires and data on relapse, mortality, BMI, cardiovascular parameters and serum lipid values will be collected. Discussion: This study will determine the effect of modifying the dietary fat content on AP recurrence, mortality, serum lipids and weight loss in idiopathic cases.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pancreatology. - 22 : 1 (2022), p. 51-57. -
További szerzők:Vereczkei Zsófia Ocskay Klementina Szakó Lajos Farkas Nelli Szakács Zsolt Zádori Noémi Wilschanski, Michael Pandol, Stephen J. Joly, Francisca Capurso, Gabriele Arcidiacono, Paolo Giorgio Izbéki Ferenc Czakó László Papp Mária (1975-) (belgyógyász, gasztroenterológus) Czopf László Hegyi Péter Jr. (belgyógyász) Párniczky Andrea (gyermekgyógyász) Hungarian Pancreatic Study Group
Pályázati támogatás:GINOP-2.3.2-15-2016-00048
GINOP
EFOP-3.6.2-16-2017-00006
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM083103
Első szerző:Koncz Balázs
Cím:LIFEStyle, Prevention and Risk of Acute PaNcreatitis (LIFESPAN) : protocol of a multicentre and multinational observational case-control study / Koncz Balázs, Darvasi Erika, Erdősi Dalma, Szentesi Andrea, Márta Katalin, Erőss Bálint, Pécsi Dániel, Gyöngyi Zoltán, Girán János, Farkas Nelli, Papp Maria, Fehér Eszter, Vitális Zsuzsanna, Janka Tamás, Vincze Áron, Izbéki Ferenc, Dunás-Varga Veronika, Gajdán László, Török Imola, Károly Sándor, Antal Judit, Zádori Noémi, Lerch Markus M., Neoptolemos John, Sahin-Toth Miklos, Petersen Ole H., Hegyi Péter
Dátum:2020
ISSN:2044-6055 2044-6055
Megjegyzések:AbstrACt Introduction Acute pancreatitis (AP) is a life- threatening inflammatory disease of the exocrine pancreas which needs acute hospitalisation. Despite its importance, we have significant lack of knowledge whether the lifestyle factors elevate or decrease the risk of AP or influence the disease outcome. So far, no synthetising study has been carried out examining associations between socioeconomic factors, dietary habits, physical activity, chronic stress, sleep quality and AP. Accordingly, LIFESPAN identifies risk factors of acute pancreatitis and helps to prepare preventive recommendations for lifestyle elements. Methods and analysis LIFESPAN is an observational, multicentre international case?control study. Participating subjects will create case and control groups. The study protocol was designed according to the SPIRIT guideline. Patients in the case group (n=1700) have suffered from AP (alcohol- induced, n=500; biliary, n=500; hypertriglyceridemiainduced, n=200; other, n=500); the control group subjects have no AP in their medical history. Our study will have three major control groups (n=2200): hospital- based (n=500), population- based (n=500) and aetiology- based (alcohol, n=500; biliary, n=500 and hypertriglyceridemia, n=200). All of them will be matched to the case group individually by gender, age and location of residence. Aggregately, 3900 subjects will be enrolled into the study. The study participants will complete a complex questionnaire with the help of a clinical research administrator/study nurse. Analysis methods include analysis of the continuous and categorical values. Ethics and dissemination The study has obtained the relevant ethical approval (54175-2/2018/EKU) and also internationally registered (ISRCTN25940508). After obtaining the final conclusions, we will publish the data to the medical community and will also disseminate our results via open access. trial registration number ISRCTN25940508; Pre- results.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
acute pancreatitis
lifestyle
prevention
Megjelenés:BMJ Open. - 10 : 1 (2020), p. 1-9. -
További szerzők:Darvasi Erika Erdősi Dalma Szentesi Andrea Márta Katalin Erőss Bálint Pécsi Dániel Gyöngyi Zoltán Girán János Farkas Nelli Papp Mária (1975-) (belgyógyász, gasztroenterológus) Fehér Eszter Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Janka Tamás Vincze Áron Izbéki Ferenc Dunás-Varga Veronika Gajdán László Török Imola Károly Sándor Antal Judit Zádori Noémi Lerch, Markus M. Neoptoleomos, Johan P. Sahin-Tóth Miklós Petersen, Ole H. Hegyi Péter Jenő (belgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM078558
035-os BibID:(cikkazonosító)e025551 (PMID)31289058 (PMCID)PMC6629406
Első szerző:Kucserik Levente Pál
Cím:Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study) : protocol of a multicenter randomized clinical trial / Levente Pál Kucserik, Katalin Márta, Áron Vincze, György Lázár, László Czakó, Zsolt Szentkereszty, Mária Papp, Károly Palatka, Ferenc Izbéki, Áron Altorjay, Imola Török, Sorin Barbu, Marcel Tantau, András Vereczkei, Lajos Bogár, Márton Dénes, Imola Németh, Andrea Szentesi, Noémi Zádori, Judit Antal, Markus M. Lerch, John Neoptolemos, Miklós Sahin-Tóth, Ole H. Petersen, Dezső Kelemen, Péter Hegyi
Dátum:2019
ISSN:2044-6055
Megjegyzések:Introduction. According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomized, controlled multicenter trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy. We hypothesize that carrying out a sphincterotomy (ES) allows us to delay cholecystectomy, thus making it logistically easier to perform and potentially increasing the efficacy and safety of the procedure. Methods/Design. EMILY is a prospective, randomized, controlled multicenter trial. All patients with mild ABP, who underwent ES during the index admission, or in the medical history will be informed to take part in EMILY study. The patients will be randomized into two groups: (1) early cholecystectomy (within 6 days after discharge) and (2) patients with delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 93 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The secondary endpoints are organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications. Ethics and dissemination. The trial has been registered at the ISRCTN (ref no. 10667869) and approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
acute biliary pancreatitis
cholecystectomy
endoscopic sphincterotomy
Megjelenés:BMJ Open. - 9 : 7 (2019), p. 1-8. -
További szerzők:Márta Katalin Vincze Áron Lázár György Czakó László Szentkereszty Zsolt (1961-) (sebész) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Izbéki Ferenc Altorjay Áron Török Imola Barbu, Sorin Tantau, Marcel Vereczkei András Bogár Lajos Dénes Márton Németh Imola Szentesi Andrea Zádori Noémi Antal Judit Lerch, Markus M. Neoptoleomos, Johan P. Sahin-Tóth Miklós Petersen, Ole H. Kelemen Dezső Hegyi Péter Jenő (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM100014
035-os BibID:(cikkazonosító)e050821 (WoS)000739490700018 (Scopus)85122762723
Első szerző:Ocskay Klementina
Cím:Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR) : protocol of a randomised controlled trial and a cohort study / Klementina Ocskay, Márk Félix Juhász, Nelli Farkas, Noémi Zádori, Lajos Szakó, Zsolt Szakács, Andrea Szentesi, Bálint Erőss, Emőke Miklós, Antal Zemplényi, Béla Birkás, Árpád Csathó, István Hartung, Tamás Nagy, László Czopf, Ferenc Izbéki, László Gajdán, Mária Papp, László Czakó, Dóra Illés, Marco V. Marino, Antonello Mirabella, Ewa Małecka-Panas, Hubert Zatorski, Yaroslav Susak, Kristina Opalchuk, Gabriele Capurso, Laura Apadula, Cristian Gheorghe, Ionut Adrian Saizu, Ole H. Petersen, Enrique de-Madaria, Jonas Rosendahl, Andrea Párniczky, Péter Hegyi, Hungarian Pancreatic Study Group
Dátum:2022
ISSN:2044-6055
Megjegyzések:Background/objectives Acute recurrent pancreatitis (ARP) due to alcohol and/or tobacco abuse is a preventable disease which lowers quality of life and can lead to chronic pancreatitis. The REAPPEAR study aims to investigate whether a combined patient education and cessation programme for smoking and alcohol prevents ARP. Methods and analysis The REAPPEAR study consists of an international multicentre randomised controlled trial (REAPPEAR-T) testing the efficacy of a cessation programme on alcohol and smoking and a prospective cohort study (REAPPEAR-C) assessing the effects of change in alcohol consumption and smoking (irrespective of intervention). Daily smoker patients hospitalised with alcohol-induced acute pancreatitis (AP) will be enrolled. All patients will receive a standard intervention priorly to encourage alcohol and smoking cessation. Participants will be subjected to laboratory testing, measurement of blood pressure and body mass index and will provide blood, hair and urine samples for later biomarker analysis. Addiction, motivation to change, socioeconomic status and quality of life will be evaluated with questionnaires. In the trial, patients will be randomised either to the cessation programme with 3-monthly visits or to the control group with annual visits. Participants of the cessation programme will receive a brief intervention at every visit with direct feedback on their alcohol consumption based on laboratory results. The primary endpoint will be the composite of 2-year all-cause recurrence rate of AP and/ or 2-year all-cause mortality. The cost-effectiveness of the cessation programme will be evaluated. An estimated 182 participants will be enrolled per group to the REAPPEAR-T with further enrolment to the cohort. Ethics and dissemination The study was approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (40394-10/2020/ EÜIG), all local ethical approvals are in place. Results will be disseminated at conferences and in peer-reviewed journals. Trial registration number NCT04647097
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:BMJ Open. - 12 : 1 (2022), p. 1-9. -
További szerzők:Juhász Márk Félix Farkas Nelli Zádori Noémi Szakó Lajos Szakács Zsolt Szentesi Andrea Erőss Bálint Miklós Emőke Zemplényi Antal Birkás Béla Csathó Árpád Hartung István Nagy Tamás (1977-) (vegyész, orvosi laboratóriumi analitikus) Czopf László Izbéki Ferenc Gajdán László Papp Mária (1975-) (belgyógyász, gasztroenterológus) Czakó László Illés Dóra Marino, Marco Vito Mirabella, Antonello Małecka-Panas, Ewa Zatorski, Hubert Susak, Yaroslav Mykhailovych Opalchuk, Kristina Capurso, Gabriele Apadula, Laura Gheorghe, Cristian Saizu, Ionut Adrian Petersen, Ole H. de-Madaria, Enrique Rosendahl, Jonas Párniczky Andrea (gyermekgyógyász) Hegyi Péter Jenő (belgyógyász) Hungarian Pancreatic Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM082674
Első szerző:Zádori Noémi
Cím:EarLy elimination of fatty acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial) : protocol of an open-label, multicenter, adaptive randomized clinical trial / Noémi Zádori, Noémi Gede, Judit Antal, Andrea Szentesi, Hussain Alizadeh, Áron Vincze, Ferenc Izbéki, Mária Papp, László Czakó, Márta Varga, Enrique de-Madaria, Ole H. Petersen, Vijay P. Singh, Julia Mayerle, Nándor Faluhelyi, Attila Miseta, István Reiber, Péter Hegyi
Dátum:2020
ISSN:1424-3903
Megjegyzések:Introduction: Acute pancreatitis (AP) is a life-threatening inflammatory disease, with no specific pharmacologi- cal treatment. However, concerning some etiologies, early specific intervention (such as ERCP in biliary AP) has proven to be remarkably beneficial. Hypertriglyceridemia (HTG) induces severe pancreatic damage by several direct (cellular damage) and indirect (deterioration of microcirculation) mechanisms. Published data suggest that early removal of triglycerides (TGs) and toxic free fatty acids (FFAs) may be advantageous; however, high-quality evidence is still missing in the literature. Methods: /Design: ELEFANT is a randomized controlled, multicenter, international trial testing the concept that early elimination of TGs and FFAs from the blood is beneficial in HTG-AP. The study will be performed with the adaptive "drop-the-loser" design, which supports the possibility of dropping the inferior treatment arm, based on the results of the interim analysis. Patients with HTG-AP defined by TG level over 11.3 mmol/l (1000 mg/dL) are randomized into three groups: (A) patients who undergo plasmapheresis and receive aggressive fluid resuscita- tion; (B) patients who receive insulin and heparin treatment with aggressive fluid resuscitation; and (C) patients with aggressive fluid resuscitation. Please note that all intervention must be started within 48 h from the onset of abdominal pain. Exclusion criteria are designed logically to decrease the possibility of any distorting effects of other diseases. The composite primary endpoint will include both severity and mortality.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Acute pancreatitis
Hypertriglyceridemia
Plasmapheresis
Free fatty acids
Heparin
Insulin
Randomized clinical trial
Megjelenés:Pancreatology. - 20 : 3 (2020), p. 369-376. -
További szerzők:Gede Noémi Antal Judit Szentesi Andrea Alizadeh, Hussain Vincze Áron Izbéki Ferenc Papp Mária (1975-) (belgyógyász, gasztroenterológus) Czakó László Varga Márta de-Madaria, Enrique Petersen, Ole H. Singh, Vijay P. Mayerle, Julia Faluhelyi Nándor Miseta Attila Reiber István Hegyi Péter (pszichológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00048
GINOP
KH-125678
Egyéb
EFOP-3.6.2-16-2017-00006
EFOP
LP2014-10/2014
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.